Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for vascular surgery. Principal product lines include anastomotic clips, vascular grafts, stent grafts, and balloon catheters. The company operates in a single segment with headquarters in Burlington, Massachusetts, and international operations in Germany, Italy, and Japan.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Net Sales | $13,656 | $41,629 |
| Gross Profit | $10,398 | $31,372 |
| Gross Margin | 76.1% | 75.4% |
| Operating Income | $2,032 | $5,310 |
| Net Income | $1,517 | $4,049 |
| Diluted EPS | $0.09 | $0.25 |
| Cash and Cash Equivalents (Sep 30, 2010) | $27,453 | |
| Long-Term Debt | $156 | |
| Net Cash Provided by Operating Activities (9 months) | $6,083 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2% ($13.7M) for the quarter and 12% ($41.6M) for the nine months compared to the prior year periods. Growth was driven by higher average selling prices and increased sales in the Vascular category (valvulotomes, vessel closure systems, biologic patches).
- Profitability: Net income surged to $4.0M for the nine months ended September 30, 2010, compared to $0.3M in the prior year period. This improvement was aided by the absence of the $1.8M restructuring charge incurred in the first quarter of 2009.
- Product Mix: Sales of TAArget and UniFit stent grafts declined significantly (55% drop in the quarter) following the decision to suspend clinical studies for these products. The company divested the OptiLock Implantable Port product line in June 2010.
- Geography: Americas sales increased 14% for the quarter, while International sales decreased 15%, largely due to currency fluctuations and declines in specific stent graft lines.
Guidance, Outlook, and Risks
- Manufacturing Reorganization: On October 27, 2010, the Board adopted a plan to relocate AlboGraft Vascular Graft production from Brindisi, Italy, to Burlington, Massachusetts. The company expects to record charges of approximately $1.8 million and cash outlays of $2.6 million (excluding employee termination benefits) starting in Q4 2010 through 2011.
- R&D Strategy Shift: The company indefinitely suspended clinical studies for TAArget and UniFit stent grafts in October 2010 to reduce R&D spending and reinvest savings into other product development and regulatory initiatives.
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($27.6M total) are sufficient to meet requirements for at least the next 12 months. The company terminated its $10M revolving credit facility in August 2010 with no borrowings outstanding.
- Tax Position: The company maintains a valuation allowance against substantially all deferred tax assets. However, if the company transitions to profitability and meets specific criteria in Q4 2010, a significant portion of this allowance may be reversed, resulting in a tax benefit.
- Risk Factors: Key risks include the successful execution of the manufacturing relocation, potential delays in union negotiations in Italy, and the impact of foreign currency exchange rate fluctuations (approx. 38% of sales are foreign-denominated).
Investor Verification Checklist
- Restructuring Costs: Verify the final amount of employee termination benefits and total cash outlays associated with the Brindisi facility closure, as these are currently subject to collective bargaining negotiations.
- Valuation Allowance Reversal: Monitor Q4 2010 results for the potential reversal of the valuation allowance on deferred tax assets, which could significantly impact net income.
- Product Transition: Confirm the timeline and cost efficiency of transferring AlboGraft manufacturing to the U.S. headquarters to ensure no disruption in supply or quality.
- Stock Repurchases: Note that the company has $3.4M remaining authority under its $5.0M stock repurchase program, which could impact share count and liquidity.